T-cell responses were evaluated prospectively in 41 patients with acute human immunodeficiency virus type 1 (HIV-1) infection (30 untreated and 11 receiving zidovudine, lamivudine, and indinavir) and in 38 uninfected adults. By 6-12 months, treated patients had significantly greater median Candida and tetanus lymphoproliferative responses (stimulation index [SI], 76 and 55, respectively) than did untreated patients (SI, 7 and 6, and .001, respectively), P = .02 and the responses of treated patients surpassed those of uninfected adults (SI, 19 and 32, and .101, respectively). Unlike the patients in the untreated group, the patients in P = .002 the treated group mounted a 6-fold increased HIV-1 p24 response (SI increase, 1.0 to 5.7, ) within 3 months. HIV-1-specific cytotoxicity remained detectable in most treated P = .01 patients. Thus, combination therapy administered within 3-4 months of infection was associated with improved T-cell memory responses that were distinct from those of untreated patients. The amplified HIV-1-specific T-cell responses may help maintain cytotoxic activities.
phocytes to provide help in the recruitment and maintenance of these effector activities.
The association of HIV-1 infection with CD4 ϩ T-cell dysfunction is manifested by impaired in vitro lymphoproliferation to recall antigens, loss of delayed-type hypersensitivity, and increased susceptibility to opportunistic infections and neoplasms [8] [9] [10] . Recent evidence indicates that CD4 ϩ T-cell dysfunction occurs soon after HIV-1 exposure [11] . The mechanisms that account for impaired T helper (Th) cell function are not completely understood but may include destruction of CD4 ϩ T cells by direct infection or apoptosis [12] [13] [14] [15] as well as disruption of the thymic and lymphoid architecture by HIV-1 [16] [17] [18] .
Thus, improvement in Th cell function may be realized only by potent and sustained suppression of HIV-1 replication. Recent studies, including this report, have begun to address this issue. Persons with advanced disease exhibit improved recognition of recall antigens, but not HIV-1 antigens, when treated with 2 reverse transcriptase inhibitors and 1 protease inhibitor [19, 20] . By contrast, a report of 3 patients in whom triple antiretroviral therapy was initiated prior to seroconversion showed induction of HIV-specific Th cell responses [21] . However, it remains uncertain how soon treatment must begin to observe HIV-1-specific effects, how long these effects persist, and whether they can be clearly distinguished from changes that occur in untreated patients in conjunction with declines in viremia after acute infection. In addition, it is not known whether general immunocompetence typical of healthy adults can be restored in HIV-1-infected patients by early treatment. Thus, to better understand these issues, we undertook a 1-year prospective study of cellular immunity in 41 patients with early HIV-1 infection, of whom 11 received open-label combination therapy and 30 were untreated. To determine whether T-cell responses in early disease are similar to responses among those whose therapy is initiated later in their disease and among immunocompetent recipients of HIV vaccines, we compared findings in the acutely infected patients with responses in 14 chronically infected subjects receiving a similar treatment regimen and in 38 uninfected subjects recruited to HIV-1 experimental vaccine trials.
Methods
Study population. Individuals with acute HIV-1 infection were enrolled at the University of Washington (UW) Primary HIV Infection Clinic during 1992-1997. Details for study eligibility have been reported elsewhere [22] . We evaluated the first 11 consecutively enrolled patients who were receiving open-label therapy with indinavir (800 mg by mouth every 8 h), zidovudine (200 mg by mouth every 8 h), and lamivudine (150 mg by mouth twice per day) and who consented to undergo the additional venipunctures required for this study. The untreated controls were 30 patients with similar demographic profiles who were matched with the treated group for duration of infection [3, 11] . Patients underwent clinical evaluation and venipuncture for virological studies weekly for the first month and then every 4 weeks for 1 year. Blood for immunological studies was obtained 1 or 2 times before treatment and then approximately every 1-2 months.
Chronically HIV-1 infected patients were participants of AIDS Clinical Trials Group 343 (substudy 879) [23] at the UW AIDS Clinical Trials Unit. These patients received zidovudine or lamivudine, indinavir, and stavudine for ∼12-18 months and maintained virologic responses of plasma HIV-1 RNA !200 copies/mL and CD4 ϩ T-cell counts 1200 cells/mL. Healthy adults participating in vaccine studies at the UW AIDS Vaccine Evaluation Unit served as HIV-1-uninfected control subjects. They were enrolled in phase I clinical trials that were testing vCP205 (Pasteur-Mérieux Connaught, Lyon, France), a live recombinant canarypox vector containing portions of HIV-1 env, gag, and pol genes.
Virological and T-cell subset analyses. Plasma HIV-1 RNA level was determined by quantitative branched-DNA (bDNA; Chiron, Emeryville, CA) and ultrasensitive reverse transcriptase-polymerase chain reaction (RT-PCR; Roche Molecular Systems, Branchburg, NJ) assays. Levels were expressed as copies/mL, and the lower levels of sensitivity were 500 copies/mL (bDNA assay) and 50 copies/mL (RT-PCR assay) [24] . We report virus levels measured by the bDNA assay at 1500 copies/mL and by the ultrasensitive RT-PCR assay (if available) when the bDNA assay was р500 copies/mL. Absolute blood CD4 ϩ T cell count was measured by use of consensus flow cytometry methods [22] .
Lymphocyte proliferation assays. Fresh peripheral blood mononuclear cells (PBMC) in RPMI with 10% heat-inactivated human serum (Biocell, Rancho Dominguez, CA), L-glutamine (1 mM), penicillin (100 U/mL), and streptomycin (100 mg/mL) were incubated in quadruplicate cultures at 10 5 cells/well in 96-well roundbottomed plates for 6 days in the presence of no antigen; 20 mg/ mL Candida and 1 mg/mL tetanus toxoid (Connaught Laboratories, Toronto, Canada); 5 mg/mL baculovirus-expressed recombinant HIV-1 MN gp160, HIV-1 LAI gp160, and HIV-1 LAI p24 (Protein Sciences, Meriden, CT); 5 mg/mL yeast-derived HIV-1 SF-2 p24 antigen; or 5 mg/mL CHO-derived HIV-1 SF-2 gp120 (Chiron) and respective control proteins. To enrich for CD4ϩ T cells in these assays, we used negative selection with anti-CD8 antibody-coated Microbeads (Miltenyl Biotec, Auburn, CA). On day 6, 1 mCi of 3 Hthymidine (NEN Products, Boston) was delivered to each well. Cells were washed and harvested after 18 h, and radioactive thymidine incorporation was measured (Packard Topcount, Meriden, CT) and expressed as counts per minute (cpm). The stimulation index (SI) was calculated as the mean cpm of stimulated cultures divided by the mean cpm of unstimulated cultures. Responses with , and generally a mean cpm 12000, were considered positive SI у 4.0 on the basis of comparisons with in vitro lymphoproliferation to these antigens and control proteins, when available, by PBMC from 1100 HIV-uninfected control subjects tested in our laboratory. Responses to HIV-1 p24 and HIV-1 gp160 refer to measurements made by use of the baculovirus-expressed recombinant HIV-1 LAI p24 and HIV-1 MN gp160, respectively, except where otherwise indicated.
Analysis of cytokine production. CD4 ϩ T-cell-enriched PBMC were incubated at cells/mL in 24-well plates in the presence 6 2 ϫ 10 of no antigen, HIV-1 LAI p24 (5 mg/mL), and HIV-1 MN gp160 (5 mg/ mL). Secretion of cytokines was measured by ELISA (Endogen, Boston) from cell culture supernatants harvested after 48 h (interleukin [IL]-4 and IL-10) and 96 h (interferon [IFN]-g), according to the manufacturer's instructions. All samples, standards, and controls were run in duplicate, and the lower limit of detection of the assay was 0.4 pg/mL.
HIV-1-specific CTL limiting dilution assays (LDAs). Precursor CTL (pCTL) frequencies were measured in the treated patients in an LDA after a 14-day stimulation, with modifications of methods described elsewhere [3] . Assays were conducted in batch analysis on cryopreserved PBMC from individual donors obtained at multiple time points. Serial dilutions of cryopreserved PBMC were plated in 96-well round-bottomed plates in 24-well replicates. Fresh autologous monocytes (3000 cells/well), infected with recombinant vaccinia virus (rVV)-encoding portions of HIV-1 env, gag, and pol genes (vP1291) (MOI,10) provided by J. Tartaglia (Virogenetics, Troy, NY) and g irradiated (3000 rad), were used as HIV-specific stimulator cells. Irradiated autologous PBMC (50,000 cells) feeder cells and 50 U/mL human recombinant IL-2 (Chiron) were added to each well.
On day 14, the 51 Cr release assay was done, as described elsewhere [3] . Radio-labeled autologous Epstein-Barr virustransformed B lymphoblastoid cell lines, previously infected with rVV and containing either HIV-1 MN env (vP1174), HIV-1 LAI gag (vP1287), HIV-1 LAI pol (vP1288), or the control WR vaccinia (Lvar; Virogenetics), served as target cells. The percentage target lysis was calculated from the mean of triplicate measurements, and wells with lysis exceeding the mean spontaneous release by 3 SDs were considered positive [3] . The precursor frequencies were calculated as described elsewhere [25] response rate, and the Wilcoxon signed rank test was used to compare these responses with those before treatment. Trajectories of SI over time were constructed by linear interpolation on the logarithmic scale. Each trajectory was assigned a score, representing the difference in the number of trajectories it enveloped and the number by which it was enveloped. A permutation test was done to compare the trajectories between the treatment and control groups. All P values were calculated as 2-sided. Scatter plots were constructed to demonstrate after-treatment trajectories of virus load and precursor CTL frequencies, and observations for each individual were connected by a line.
Results
Study population. Forty-one patients with acute HIV-1 infection consented and enrolled in the study. The mean age was 29 years in the treated group and 34 years in the untreated group. The sex, risk behavior, and prevalence of symptoms during acute infection were similar for the treated and untreated patients (table 1 ). In addition, there were no significant differences in the median time between infection acquisition and study entry, in initial plasma HIV-1 RNA levels, or in CD4 ϩ T-cell counts (table 1) .
Virus load and CD4 T-cell counts. Plasma HIV-1 RNA in the treated group declined rapidly to 53 copies/mL after 6 months and was undetectable by 12 months after treatment (table 1) . One patient who discontinued treatment at 16 weeks achieved a nadir of 122 copies/mL. By contrast, the untreated patients had significantly higher plasma HIV-1 RNA levels at both 6 months (median, 26,108 copies/mL) and 12 months (median, 36,108 copies/mL) from study entry (table 1) .
Coincident with suppression of viremia, treated patients experienced a rise in absolute peripheral blood CD4 ϩ T-cell counts. The median CD4 ϩ T-cell count increased from 654 to 763 cells/mL after 12 months of treatment. By contrast, CD4 ϩ T-cell levels in the untreated patients declined from a median of 576 cells/mL at enrollment to 459 cells/mL over the same interval of infection (table 1) . Thus, by 12 months of study, the treated patients had significantly higher levels of CD4 ϩ T cells compared with the untreated group ( ; ) to Candida and 14-fold (from 3.0 to 41.3, ) to P = .03 P = .06 tetanus within 100 days (table 2, figure 1A and B). Analysis at 50-day intervals throughout the study period revealed significantly improved recognition of recall antigens during most time points, compared with pretreatment responses (table 2, figure  1A and B) . In vitro recall antigen responses also improved over time in untreated HIV-1 infected patients, with a median SI to Candida of 7 and to tetanus of 6 at the 6-12-month interval from infection ( figure 1C and D) . However, recall responses were significantly greater in the treated than in the untreated control group, comparing the log median SI curves from time of infection for Candida ( ) and tetanus ( ). P ! .0001 P ! .0001 These results indicate that, although increases in detectable CD4 ϩ memory responses occur after acute infection, substantial improvement is associated with aggressive intervention to lower viral replication.
To determine whether the recall responses among the treated HIV-infected patients approximated those of healthy HIV-1-uninfected adults, we compared responses in the treated and untreated patients after 6-12 months of infection with those in 38 healthy adults participating in HIV-1 vaccine trials (at 6-12 months postimmunization; figure 1C and D) . The levels of lymphoproliferation to tetanus in the treated patients (median SI, 55) were similar to those in the uninfected subjects (median SI, 32;
). Surprisingly, the levels to Candida (median SI, 76) P = .10 were even higher among the treated than among the uninfected subjects (median SI, 19; ). By contrast, the median P = .002 responses to Candida (SI, 7) and tetanus (SI, 6) in the untreated HIV-1-infected patients were significantly lower than in the uninfected subjects ( and , respectively; figure P = .02 P = .001 1C and D). The proportions of responders to Candida and tetanus among the treated patients (100% for both antigens), but not among the untreated patients (71% and 64%, respectively), were similar to those in the uninfected group (92% for both antigens). Among the chronically infected treated group, only 22% of the patients mounted a response to Candida (tetanus antigen was not tested), and the median SI was 2.3 (range, 1-15). These results indicate that therapeutic suppression of HIV-1 replication during early infection is associated with enhanced recall responses to levels equivalent to those in immunocompetent uninfected individuals. In addition, those with chronic infection in whom therapy was delayed did not experience a similar enhancement.
HIV-1-specific T-cell proliferative responses. At baseline, lymphoproliferative responses to HIV-1 p24 were observed in 3 (7%) of the 41 subjects with acute infection, 2 of whom did not receive therapy and one (no. 1201) who was subsequently treated (table 2 and figure 2A) . Positive responses to HIV-1 envelope were detected in 4 (10%) of the 41 subjects, 3 of whom did not receive treatment and one (no. 1212) who was subsequently treated (table 2 and figure 2B).
Antiretroviral therapy was associated with induction of HIV-1 p24-specific lymphoproliferative responses in 6 (60%) of 10 patients at 100 days from initiation of therapy, with the median SI increasing 6-fold ( ; figure 2A and table 2 ). The median P = .01 duration of treatment associated with decline in plasma HIV-1 RNA to р50 copies/mL, 95 days, was similar to the time when the first positive Gag-specific response was observed, 97 days. Of note, patients mounted a p24-specific response regardless of whether treatment was initiated within the first 6 weeks of infection (3 patients) or delayed until 4 months after infection (3 patients). The Gag-specific responses persisted in the majority of patients over the 1-year treatment period, but the levels increased only minimally above those within the initial 8-12 weeks ( figure 2A, table 2 ). Moreover, the median level of T-cell proliferation to p24 antigen was nearly 4-fold lower than to recall antigens ( figures 1 and 2) .
To further test whether the T-cell proliferation was specific for HIV-1 Gag protein, we examined responses to p24 antigen prepared by a different expression system and representing a different HIV-1 strain (yeast-derived HIV-1 SF-2 p24 antigen) in 8 treated patients. Of the 24 positive responses to the baculovirus-derived HIV-1 LAI antigen, we observed 12 (50%) concur- rent positive responses to the yeast-derived HIV-1 SF-2 p24 antigen. Conversely, among the 15 responses to the yeast-derived p24 antigen, we detected 12 (80%) positive responses to the baculovirus-derived preparation. Overall, the SIs were commonly 2-to 4-fold higher to the baculovirus-derived antigen.
The increase in HIV-1 gp160-specific T-cell proliferation was less marked than that in HIV-1 p24-specific lymphoproliferation. When examined at 50-day intervals after treatment, the median SI was never у3.0, and the responses, when positive, were rarely sustained (table 2, figure 2B ). These findings extended to lymphoproliferation to other HIV-1 envelope antigens on the basis of various prototype strains (HIV-1 LAI , HIV-1 SF-2 ; data not shown).
HIV-1 p24-specific proliferative responses were notably different between the treated and untreated patients ( figure 2C ). The untreated patients rarely developed p24-specific lymphoproliferation, and, over each 50-day interval, the median SI of the group remained !4.0. Thus, comparing the log median SI to p24 antigen curves from time of infection, responses in the treated patients were significantly higher than those in the untreated patients ( ; figure 2C) . The treated group also P ! .0001 exhibited higher envelope-specific lymphoproliferation in com- parison with the untreated patients ( ; figure 2D ). How-P = .01 ever, this difference is of questionable significance, because median responses in both groups were below the level of cutoff for a positive response.
Thus, the use of potent antiretrovirals in early-infected patients was associated with an increase in Gag-specific T-cell responses. However, it remained unclear whether this effect was restricted to patients who received treatment during early infection. Therefore, we compared responses in the treated acutely infected patients with 14 chronically infected patients receiving a similar treatment regimen for ∼12-18 months (figures 2C and D). Of note, patients with advanced infection exhibited responses to neither the Gag (median SI, 1; range, 1-3; figure  2C ) nor the envelope proteins (median SI, 1; range, 1-2; figure  2D ). These results indicated that treatment in early rather than later infection was associated with the emergence of Gag-specific responses.
To evaluate the magnitude of the HIV-1-specific responses in the infected patients relative to those induced by experimental HIV-1 vaccines in immunocompetent persons, we compared lymphoproliferative SI in the infected persons at 6-12 months from infection with responses in the vaccinees at 6-12 months from immunization ( figure 2C and D) . We selected a vaccination regimen consisting of 3-5 doses of recombinant canarypox that expresses HIV-1 genes including env and gag [26] , which has elicited one of the highest frequencies of Gag-specific cytotoxic T-cell response among immunogens tested thus far in the AIDS Vaccine Evaluation Group (unpublished data). The median SI to HIV-1 p24 in the treated patients was significantly greater ( ) than in the vaccine recipients (SI, 13.5 vs. 2.5, re-P = .0001 spectively;
; figure 2C ). However, the median SI to P = .0001 HIV-1 gp160 was not significantly different between the 2 groups (SI, 2.5 vs. 4, respectively;
; figure 2D ). By con-P = .46 trast, responses to p24 and gp160 among the untreated patients (median SI of 1.0 for both) were significantly lower than among vaccine recipients ( and .0004, respectively; figure 2C P = .008 and D). Overall, the proportion of responders to HIV-1 p24 among the treated patients (100%) but not the untreated group (0%) was higher than among the vaccine recipients (53%).
CD4 ϩ T-cell-mediated lymphoproliferation and cytokine production. To determine whether the HIV-1 p24-specific T-cell responses were mediated by CD4 ϩ T cells and associated with the secretion of antiviral cytokines, we enriched PBMC for CD4 ϩ T cells, stimulated them with HIV-1 antigens, and measured their proliferation and cytokine secretion. The CD4 ϩ Tcell proliferation to HIV-1 p24 antigen in these patients was, on average, 2.5-fold higher (range, 1-4) than by bulk PBMC ( figure 3A) , indicating that the Gag-specific responses are mediated predominantly by CD4 ϩ T cells. Next we sought to determine the Th cell cytokine profile of the Gag-specific CD4ϩ T cells after in vitro stimulation with p24 antigen. Marked proliferation by CD4ϩ T cells to p24 antigen (figure 3B) was associated with secretion of high levels of IFN-g (268.7 pg/mL), in contrast to very low levels with medium alone (2.1 pg/mL) ( figure 3C ) and the baculovirus control protein (4.8 pg/mL). Alternatively, secretion of IL-4 and IL-10 were minimal and not different from levels in cultures with medium alone. Thus, antiviral therapy in early-infected patients is associated with a Th1 CD4 ϩ T-cell-mediated Gagspecific response.
HIV-1-specific cytotoxicity. To determine the effect of suppression of plasma viremia on antigen-specific cytotoxicity, we compared the pretreatment (1 or 2 time points) HIV-1-specific pCTL frequencies with those up to 48 weeks after treatment (4-6 time points) in 9 patients (figure 4). HIV-1-specific pCTL frequencies were variable over time but were sustained in the majority of treated patients. Memory CTL responses were detected in 7 of the 9 (nos. 1155, 1166, 1168, 1184, 1201, 1208, and 1216) patients before treatment. They were all maintained during the period of precipitous decline in plasma viremia, as well as during the subsequent interval of virus suppression in Figure 4 . Effect of treatment on plasma viremia and cytotoxic T-lymphocyte precursor (pCTL) frequencies. Cytolytic activities are expressed as pCTL per 10 6 peripheral blood mononuclear cells (PBMC), on basis of lysis of autologous B-lymphoblastoid cell lines infected with recombinant vaccinia expressing human immunodeficiency virus type 1 (HIV-1) Env (᭡), Gag (ⅷ), Pol (Ⅵ), or control protein, in 24 replicate wells. Graphs depict pCTL frequencies specific for individual HIV-1 gene products after subtracting the pCTL frequencies for the control protein. Plasma HIV-1 RNA levels (⅜) were determined by branched-chain DNA amplification (1500 copies/mL) and reverse transcriptase-polymerase chain reactionbased (50-500 copies/mL) assays.
all treated patients except patient no. 1155, who with initiation of therapy had a rapid decline in plasma viremia to undetectable levels and no rebound over the duration of follow-up ( figure  4) . Two of the 9 subjects (nos. 1192 and 1196) who lacked detectable pCTL prior to treatment developed responses as therapy ensued in conjunction with improved Th cell responses. Increases in pCTL frequencies were often noted, either accompanying (nos. 1166, 1168, 1196) or preceding (nos. 1184, 1201, 1208) bursts of detectable HIV-1 RNA in plasma. These results suggest that viral replication below the threshold of detection of current assays may maintain the memory cytotoxic pool, particularly in association with improved Th cell responses.
Discussion
When a patient receives a diagnosis of HIV-1 infection, there is concern that irreparable immune destruction has already occurred. Our study provides optimism that this may not be the case if patients are willing to undergo aggressive treatment with antiretroviral agents early in HIV-1 infection. We demonstrate in this prospective study that Th cell responses to previously exposed antigens (i.e., tetanus and Candida) are restored with the suppression of viral replication. Although some improvement in recall responses is expected in untreated patients as plasma viremia falls [11] , we provide evidence that only with early treatment can Th cell responses return to levels approximating those in healthy immunocompetent HIV-1-uninfected persons.
Surprisingly, responses to Candida but not tetanus in the treated patients were significantly greater than in the uninfected control subjects. Some patients experienced oral candidiasis during acute infection [22] , and this occurred in 4 of our 41 study patients (1 of 11 before treatment and 3 of 30 untreated; M. Berrey, unpublished data). Of note, 4 of the untreated patients and none of the treated patients subsequently developed Candida infection (1 recurrent, 3 new infections). Although these results should not be overinterpreted, they suggest that susceptibility to candidiasis during early infection may be reduced by treatment and that this may be associated with an enhanced antigen-specific Th cell response. These observations merit further study prospectively in additional patients to determine whether the lymphoproliferative responses are markers that reflect clinical benefit with early therapy.
We confirm recent findings [21] that patients who are treated early mount detectable Th cell responses to HIV-1. HIV-1-specific responses, typically absent among patients at all disease stages [10, 11, [27] [28] [29] except nonprogressive infection [21] , are observed in the early-treated patients but remain impaired in the untreated group. Our results indicate that, as plasma viremia falls to levels that are nearly undetectable with treatment, the CD4 ϩ T cell-mediated HIV-1 Gag-specific Th cell response emerges, which can be sustained for at least 1 year, the duration of our observation. Moreover, our data suggest that these responses are of the Th1 phenotype and are associated with the secretion of the antiviral cytokine, IFN-g.
Gag-specific responses were noted transiently in acute infection in a few patients, implying that implementation of potent antiretrovirals soon thereafter may both prevent the destruction and permit the amplification of the HIV-1-specific CD4 ϩ memory population. These results, along with others [17] , suggest that, over time, HIV-1 may deplete the CD4 ϩ T-cell pool, and the repertoire may not be amenable to complete restoration. Taken together, these findings affirm the necessity of intervening early to permit the induction of HIV-specific T-cell immunity, which ultimately may lead to improved control of HIV-1 replication by secreting antiviral cytokines and providing help for humoral and CTL effector responses.
Our findings suggest that induction of HIV-1-specific CD4 ϩ T-cell responses may occur soon after exposure to HIV-1, but unless treatment ensues to control HIV-1 viremia efficiently, these responses become undetectable. Nevertheless, 3 patients who experienced a delay in initiation of therapy up to 4 months after infection demonstrated restoration of recall and new HIV-1 p24 antigen-specific responses. Furthermore, when we compared the magnitude of HIV-1 p24-specific responses in these patients with those in patients treated within 6 weeks of infection, no appreciable differences were observed. These observations suggest that the interval between acquisition of infection and initiation of treatment in association with preservation of HIV-1-specific Th cell activities may be longer than appreciated, although, as reported elsewhere [19, 20] , when treatment was initiated in advanced infection, HIV-specific responses remained absent. Whether responses will eventually emerge in these chronically infected patients with longer treatment remains to be ascertained. Despite early therapy, none of the patients demonstrated strong or persistent HIV-1 gp160-proliferative responses. Apart from the well-recognized immunodominance of certain Gag epitopes, it remains unclear why Gag-but not envelope-specific responses are induced or restored, particularly because Th cell epitopes have been described in the envelope protein. This may be attributed to the preferential loss during acute viremia of HIV-1 envelope-specific precursor cells through infection and enhanced programmed cell death. Alternatively, this may reflect the variability in envelope epitopes between infecting strains and those represented by the antigens used in the assays, or differences in processing and presentation of the epitopes, both exogenous and endogenous, by major histocompatibility complex class II molecules. There also remains the possibility that, with additional years of treatment, detectable envelope-specific responses will emerge, which we will examine in ongoing studies.
The persistence of memory CTL responses in the setting of reduced virus load was somewhat unexpected, yet several explanations may account for this observation. First, although plasma HIV-1 RNA levels are undetectable by sensitive PCR methods, latent reservoirs of virus remain integrated in resting memory CD4 ϩ T cells [30, 31] , and low levels of active viral replication may emerge from this source and maintain the memory CTL pool. Second, enhanced T-cell help, as demonstrated here by induction of HIV-1 p24 antigen-specific responses, may maintain cytotoxic activities. This paradigm is well recognized in numerous animal models of viral infection [32, 33] , as well as in more recent studies in patients with cytomegalovirus infection [34] . Thus, the net effect of early treatment may be to maintain the pCTL for surveillance, allowing these committed cells to rapidly differentiate to effectors and contain active replicating virus. Of note, we were unable to compare the pCTL frequencies between the treated and untreated groups, because the assays in the former were done by use of cryopreserved effectors in batch analyses, whereas assays in the latter were done by use of fresh effectors, and cryopreserved cell numbers were insufficient to repeat these analyses.
These results, obtained by use of LDAs to quantitate cyto-toxicity, must be considered in view of recent technological advances in the detection of antigen-specific T cells that measure binding of cells to multimeric class I-peptide complexes or expression of IFN-g after recognition of cognate peptide with antigen-presenting cells. Because our objective was to assess the effect of therapy on the HIV-1-specific CTL memory pool, we used the LDA. Although less sensitive than the latter methods, the LDA remains the best approach currently available to assess the memory pool in patients with diverse HLA types by measuring the frequencies of memory precursors with growth potential through in vitro antigenic stimulation [35] . Thus, declines in CTL activities noted by Ogg et al. [36] in 9 subjects at various stages of HIV infection who received combination therapy were not appreciated in our study. This may largely reflect the use of distinct methods that measure different HIV-1 specificities, levels of effector activation and differentiation, and time points after treatment. In summary, these results indicate that early treatment may preserve the immune repertoire and restore antigen-specific Th cell function. Future studies are needed to identify the essential components of HIV-1-specific immunity that is sufficient to permit subsequent interruption or cessation of drugs without hazard, as well as the minimum treatment requirements to achieve this immunologic effect. More importantly, we need the infrastructure and resources internationally to provide access to HIV screening and counseling, monitoring of treatment and side effects, medication adherence, and drug resistance, so that efforts to provide less complex and more effective HIV-1 treatment globally becomes more than a remote possibility.
